ATHEROGENICS REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS

AtheroGenics, Inc., a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today reported financial results for the first quarter ended March 31, 2006. During the quarter, AtheroGenics recorded revenue of $4.2 million related to its recent licensing collaboration with AstraZeneca for the development and commercialization of its cardiovascular drug candidate, AGI-1067. CCN Matthews (http://www.ccnmatthews.com/news/releases/show.jsp?action=showRelease&searchText=false&showText=all&actionFor=590109)